![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
December 19, 2023
The co-chairs reflect on the year's key accomplishments and look ahead to 2024
December 19, 2023
In November, the cancer research community lost a trailblazer in cancer research and community oncology who was a national champion for diversity
December 19, 2023
This randomized phase 3 trial is testing whether second-line treatment with hepatic arterial infusion and systemic chemotherapy is more effective than systemic chemotherapy alone
December 19, 2023
The Fall 2023 Group Meeting was notable for a prominent increase in attention to diversity, equity, and inclusion
December 19, 2023
Elevating the role of APPs as partners in the clinic will help to reinforce the important role clinical trials play in cancer care and strengthen accrual efforts
December 19, 2023
In an annual evaluation, 46 member networks and programs met rigorous standards established by ECOG-ACRIN to indicate exemplary cancer research
December 19, 2023
These four lung cancer treatment trials are all open and enrolling patients
December 16, 2023
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
October 19, 2023
Advanced Practice Providers Working Group debuts soon; community-focused column highlights genetic testing challenges; real-world data efforts accelerate
October 19, 2023
Through a series of blood tests and patient questionnaires, this prospective observational study examines how exposures to trauma and other adverse life experiences alter the activity of genes, immune cells, and subsequent health outcomes
October 19, 2023
This randomized phase 3 trial explores repeated focused radiation to control disease and spare patients with renal cell carcinoma from systemic therapy for months or even years
October 19, 2023
This randomized phase 2 study is assessing if chemotherapy plus immunotherapy is superior to immunotherapy alone for patients with operable MSI-H/dMMR gastric and/or gastroesophageal junction cancer